/PRNewswire/ -- A new clinical trial funded by Breakthrough T1D recently launched and is testing islet cell transplantation paired with Eledon Pharmaceuticals'... 21, 2026 /PRNewswire/ -- A new clinical trial funded by Breakthrough T1D recently launched and is testing islet cell transplantation paired with Eledon Pharmaceuticals' investigational immunosuppression therapy tegoprubart in people living with type 1 diabetes (T1D) and chronic kidney disease (CKD). The first participant in the trial received an islet cell transplant, marking the first time individuals with T1D and CKD have been included in islet transplant trials. Nearly one in three people living with T1D develop CKD, which increases the risk of kidney failure and other T1D complications. Treatment options for these individuals have remained limited, and until now, potential kidney toxicity related to standard immunosuppressant regimens used in transplants has kept people with T1D and reduced kidney function out of islet cell transplant studies. "Advancing promising islet cell research that is a next step toward durable and scalable cures for type 1 diabetes is a key priority for Breakthrough T1D," said Esther Latres, Ph.D., Breakthrough T1D senior vice president, Research. "We're proud to support this trial that expands cell therapy research and access to people living with T1D and chronic kidney disease for the first time." "This first transplant represents a milestone towards expanding islet cell therapy to a broader population of people living with type 1 diabetes, including those with kidney disease who have historically been excluded from these studies," said Piotr Witkowski, M.D., Ph.D., director of the Pancreatic and Islet Transplant Program at the University of Chicago and principal investigator of the trial. "By replacing tacrolimus with tegoprubart, we hope to protect both the transplanted islets and our patients' kidney function, and show that more people with T1D can safely benefit from this therapy." The multi-center trial is currently enrolling 10 participants at the University of Chicago and the University of Miami. Eligible participants must be 18-70 years old, diagnosed with T1D for more than five years with onset before age 40, living with CKD at stage 1, 2, or 3a, and have impaired awareness of hypoglycemia. This new trial builds on the current Breakthrough T1D-funded study testing tegoprubart with deceased-donor islets transplants in people with severe hypoglycemic events or hypoglycemia unawareness.

Original title: “Breakthrough T1D Funded Clinical Trial Testing Islet Cell Transplantation with Eledon's Tegoprubart Expands to Include People with Type 1 Diabetes and Kidney Disease”

extensive parenchymal brain calcification in a patient with autosomal dominant polycystic kidney disease and stage 5 chronic kidney disease

Original title: “Extensive Parenchymal Brain Calcification in a Patient With Autosomal Dominant Polycystic Kidney Disease and Stage 5 Chronic Kidney Disease.”

A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD. Observational design, potential immortal-time bias, residual confounding, limited dosing/adherence data, and short follow-up constrain causal inference, reinforcing the need for confirmatory randomized trials.SHOW MORE · A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD. ... Adding a glucagon-like peptide-1 receptor agonist (GLP-1 RA) to ongoing SGLT2 inhibitor therapy was associated with lower risks of kidney disease progression, The FDA has approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatments for those with disease progression. "The addition of a GLP-1 RA to ongoing SGLT2 [inhibitor] therapy is associated with a substantial reduction in the risk of kidney disease progression and cardiovascular events in a real-world setting,” they wrote. "…While confirmatory randomized trials are awaited, these data support the early adoption of combination therapy to address the high residual risk in patients with CKD.” The primary outcome was major adverse kidney events (MAKE), a composite of all-cause mortality, progression to end-stage kidney disease (ESKD), dialysis, stage 5 CKD, or kidney transplant. Over a median follow-up of 12 months, combination therapy was associated with a lower risk of MAKE compared with SGLT2 inhibitor monotherapy (HR, 0.70; 95% CI, 0.65-0.74; P < .001).

Original title: “Combo GLP-1 RA, SGLT2 Therapy Linked to Lower Kidney, CV Risks | AJMC”

ultrasonographic features of the kidney in patients with frasier syndrome and stage 5 chronic kidney disease a case report and literature review

Original title: “Ultrasonographic Features of the Kidney in Patients With Frasier Syndrome and Stage 5 Chronic Kidney Disease: A Case Report and Literature Review.”

fan1 mutation and karyomegalic nephropathy in chronic kidney disease

Original title: “FAN1 mutation and karyomegalic nephropathy in chronic kidney disease.”

asymptomatic medullary thyroid carcinoma with isolated carcinoembryonic antigen elevation in a patient with chronic kidney disease a case report

Original title: “Asymptomatic Medullary Thyroid Carcinoma With Isolated Carcinoembryonic Antigen Elevation in a Patient With Chronic Kidney Disease: A Case Report.”

metabolomic responses to oral glucose tolerance test and hyperinsulinemic euglycemic clamp in ckd

Original title: “Metabolomic Responses to Oral Glucose Tolerance Test and Hyperinsulinemic-euglycemic Clamp in CKD.”

hypertriglyceridemia chronic kidney disease and proteinuria a rare case of apolipoprotein c ii amyloidosis

Original title: “[Hypertriglyceridemia, Chronic Kidney Disease, and Proteinuria: A Rare Case of Apolipoprotein C-II Amyloidosis].”

impact of acute kidney injury on hospitalization outcomes in patients with chronic kidney disease undergoing cardiac procedures with cardiopulmonary bypass in the united states

Original title: “Impact of Acute Kidney Injury on Hospitalization Outcomes in Patients with Chronic Kidney Disease Undergoing Cardiac Procedures with Cardiopulmonary Bypass in the United States.”

clinical and genetic characteristics of hypoparathyroidism deafness and renal dysplasia syndrome in a chronic kidney disease cohort

Original title: “Clinical and genetic characteristics of hypoparathyroidism, deafness, and renal dysplasia syndrome in a chronic kidney disease cohort.”

sglt2 inhibitors and outcomes in elderly patients with chronic kidney disease a narrative review

Original title: “SGLT2 Inhibitors and Outcomes in Elderly Patients With Chronic Kidney Disease: A Narrative Review.”

calciphylaxis in chronic kidney disease a systematic review of pathomechanisms and risk factors for calcific uremic arteriolopathy

Original title: “Calciphylaxis in chronic kidney disease: a systematic review of pathomechanisms and risk factors for calcific uremic arteriolopathy.”

chronic kidney disease from mineral dysregulation to bone and cardiovascular disease

Original title: “Chronic kidney disease: from mineral dysregulation to bone and cardiovascular disease.”

The Food and Drug Administration (FDA) is classifying the prognostic test for assessment of chronic kidney disease progression into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the prognostic test for assessment of chronic kidney disease progression. We are taking this action because we have determined that classifying the device into class II will provide a reasonable

Original title: “Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Prognostic Test for Assessment of Chronic Kidney Disease Progression”

REDWOOD CITY, Calif., July 21, ... a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, today announced that the first patient has been randomized in its global Phase 2b trial of AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for the treatment of ... REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, today announced that the first patient has been randomized in its global Phase 2b trial of AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. R1 Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of first-in-class therapies for patients with kidney disease. It is being conducted at multiple clinical sites across the US and in China through R1's global partnership with Alebund Pharmaceuticals (Jiangsu) Limited (HKEX: 09637) ("Alebund"). Hyperphosphatemia is one of the most common complications of advanced CKD and is almost universal in patients on dialysis. It is an independent risk factor for cardiovascular disease, bone disease, and mortality,1 yet more than 70% of US dialysis patients fail to achieve normal phosphate levels.2 Phosphate binders, the standard of care for 60 years, are limited by high pill burden and suboptimal gastrointestinal tolerance, contributing to poor adherence.3 Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis, a condition associated with serious bone and cardiovascular complications and poorer outcomes when phosphate remains uncontrolled. AP306 is a first-in-class pan phosphate active transport inhibitor designed to block three key phosphate transporters in the gut, with the potential to deliver rapid and effective phosphate lowering with a significantly reduced treatment burden.

Original title: “R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis - BioSpace”

Learn why CKD often goes undiagnosed in type 2 diabetes and how UACR screening plus obesity therapies can cut cardiovascular risk. He highlighted the essential role of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in reducing morbidity and mortality. Furthermore, the conversation addressed the importance of overcoming clinical inertia to ensure these life-prolonging therapies are initiated and maintained early in the disease course. In this episode, ‘Foundational Therapy Approaches to Mitigate Long-Term CRM Complications,’ the expert cardiologist explored the following questions: MASLD/MASH is strongly associated with obesity, type 2 diabetes, and cardiovascular disease, with obesity increasing MASLD risk dramatically. What are the key unmet treatment needs across MASH populations?

Original title: “Foundational Therapy Approaches to Mitigate Long-Term CRM Complications | AJMC”